TY - JOUR
T1 - COVID-19 vaccine perceptions and uptake in a national prospective cohort of essential workers
AU - Lutrick, Karen
AU - Groom, Holly
AU - Fowlkes, Ashley L.
AU - Groover, Kimberly D.
AU - Gaglani, Manjusha
AU - Rivers, Patrick
AU - Naleway, Allison L.
AU - Nguyen, Kimberly
AU - Herring, Meghan
AU - Dunnigan, Kayan
AU - Phillips, Andrew
AU - Parker, Joel
AU - Mayo Lamberte, Julie
AU - Prather, Khaila
AU - Thiese, Matthew S.
AU - Baccam, Zoe
AU - Tyner, Harmony
AU - Yoon, Sarang
N1 - Funding Information:
Supported by the National Center for Immunization and Respiratory Diseases and the Centers for Disease Control and Prevention (contracts 75D30120R68013 to Marshfield Clinic Research Institute, 75D30120C08379 to the University of Arizona, and 75D30120C08150 to Abt Associates).
Funding Information:
Supported by the National Center for Immunization and Respiratory Diseases and the Centers for Disease Control and Prevention (contracts 75D30120R68013 to Marshfield Clinic Research Institute, 75D30120C08379 to the University of Arizona, and 75D30120C08150 to Abt Associates). Mark G. Thompson, Lauren Grant, Young M. Yoo, Gregory Joseph, Josephine Mak, Monica Dickerson, Suxiang Tong, John Barnes, Eduardo Azziz-Baumgartner, Melissa L. Arvay, Preeta Kutty, Alicia M. Fry, Lenee Blanton, Jill Ferdinands, Anthony Fiore, Aron Hall, Adam MacNeil, L. Clifford McDonald, Mary Reynolds, Sue Reynolds, Stephanie Schrag, Nong Shang, Robert Slaughter, Matthew J. Stuckey, Natalie Thornburg, Jennifer Verani, Vic Veguilla, Rose Wang, Bao-Ping Zhu, William Brannen, Stephanie Bialek, CDC; Jefferey L. Burgess, Shawn Beitel, Patrick Rivers, Xiaoxiao Sun, Joe K. Gerald, Katherine Ellingson, Ed Bedrick, Janko Nikolich-?ugich, Genesis Barron, Dimaye Calvo, Esteban Cardona, Andrea Carmona, Alissa Coleman, Emily Cooksey, Kiara Earley, Natalie Giroux, Sofia Grijalva, Allan Guidos, Adrianna Hernandez, James Hollister, Theresa Hopkins, Rezwana Islam, Krystal Jovel, Olivia Kavanagh, Jonathan Leyva, Sally Littau, Amelia Lobos, James Lopez, Veronica Lugo, Jeremy Makar, Taylor Maldonado, Enrique Marquez, Allyson Munoz, Assumpta Nsengiyunva, Joel Parker, Jonathan Perez Leyva, Alexa Roy, Saskia Smidt, Isabella Terrazas, Tahlia Thompson, Heena Timsina, Erica Vanover, Mandie White, April Yingst, Kenneth Komatsu, Elizabeth Kim, Karla Ledezma, University of Arizona, Arizona Department of Health Services; David Engelthaler, Translational Genomics Research Institute; Lauren E.W. Olsho, Danielle R. Hunt, Laura J. Edwards, Meredith G. Wesley, Tyler C. Morrill, Brandon P. Poe, Brian Sokol, Andrea Bronaugh, Tana Brummer, Hala Deeb, Rebecca Devlin, Sauma Doka, Tara Earl, Jini Etolue, Deanna Fleary, Jessica Flores, Chris Flygare, Isaiah Gerber, Louise Hadden, Jenna Harder, Lindsay LeClair, Nancy McGarry, Peenaz Mistry, Steve Pickett, Khaila Prather, David Pulaski, Rajbansi Raorane, Meghan Shea, John Thacker, Matthew Trombley, Pearl Zheng, Chao Zhou, Abt Associates; Spencer Rose, Tnelda Zunie, Michael E. Smith, Kempapura Murthy, Nicole Calhoun, Claire Mathenge, Arundhati Rao, Manohar Mutnal, Linden Morales, Shelby Johnson, Alejandro Arroliga, Madhava Beeram, Joel Blais, Jason Ettlinger, Angela Kennedy, Natalie Settele, Rupande Patel, Elisa Priest, Jennifer Thomas, Baylor Scott & White Health; Jennifer L. Kuntz, Yolanda Prado, Daniel Sapp, Mi Lee, Chris Eddy, Matt Hornbrook, Danielle Millay, Dorothy Kurdyla, Ambrosia Bass, Kristi Bays, Kimberly Berame, Cathleen Bourdoin, Carlea Buslach, Jennifer Gluth, Kenni Graham, Tarika Holness Enedina Luis, Abreeanah Magdaleno, DeShaun Martin, Joyce Smith-McGee, Martha Perley, Sam Peterson, Aaron Piepert, Krystil Phillips, Joanna Price, Sperry Robinson, Katrina Schell, Emily Schield, Natosha Shirley, Anna Shivinsky, Britta Torgrimson-Ojerio, Brooke Wainwright, Shawn Westaway, Kaiser Permanente Northwest; Jennifer Meece, Elisha Stefanski, Lynn Ivacic, Jake Andreae, Adam Bissonnette, Krystal Boese, Michaela Braun, Cody DeHamer, Timothy Dziedzic, Joseph Eddy, Heather Edgren, Wayne Frome, Nolan Herman, Mitchell Hertel, Erin Higdon, Rosebud Johnson, Steve Kaiser, Tammy Koepel, Sarah Kohn, Taylor Kent, Thao Le, Carrie Marcis, Megan Maronde, Isaac McCready, Nidhi Mehta, Daniel Miesbauer, Anne Nikolai, Brooke Olson, Lisa Ott, Cory Pike, Nicole Price, Christopher Reardon, Logan Schafer, Rachel Schoone, Jaclyn Schneider, Tapan Sharma, Melissa Strupp, Janay Walters, Alyssa Weber, Reynor Wilhorn, Ryan Wright, Benjamin Zimmerman, Marshfield Clinic Research Laboratory; Angela Hunt, Jessica Lundgreen, Karley Respet, Jennifer Viergutz, Daniel Stafki, St. Luke's Regional Health Care System; Alberto J. Caban-Martinez, Natasha Schaefer-Solle, Paola Louzado Feliciano, Carlos Silvera, Karla Montes, Cynthia Beaver, Katerina Santiago, University of Miami; Rachel T. Brown, Camie Schaefer, Arlyne Arteaga, Matthew Bruner, Daniel Dawson, Emilee Eden, Jenna Praggastis, Joseph Stanford, Jeanmarie Mayer, Marcus Stucki, Riley Campbell, Kathy Tran, Madeleine Smith, Braydon Black, Madison Tallman, Chapman Cox, Derrick Wong, Michael Langston, Adriele Fugal, Fiona Tsang, Maya Wheeler, Gretchen Maughan, Taryn Hunt-Smith, Nikki Gallacher, Anika DSouza, Trevor Stubbs, Iman Ibrahim, Ryder Jordin, University of Utah; Marilyn J. Odean, Whiteside Institute for Clinical Research; Allen Bateman, Erik Reisdorf, Kyley Guenther, Erika Hanson, Wisconsin State Laboratory of Hygiene; the HEROES-RECOVER participants.
Funding Information:
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Allison L. Naleway reported funding from Pfizer for a meningococcal B vaccine study unrelated to the submitted work.
Publisher Copyright:
© 2021 The Authors
PY - 2022/1/24
Y1 - 2022/1/24
N2 - Introduction: In a multi-center prospective cohort of essential workers, we assessed knowledge, attitudes, and practices (KAP) by vaccine intention, prior SARS-CoV-2 positivity, and occupation, and their impact on vaccine uptake over time. Methods: Initiated in July 2020, the HEROES-RECOVER cohort provided socio-demographics and COVID-19 vaccination data. Using two follow-up surveys approximately three months apart, COVID-19 vaccine KAP, intention, and receipt was collected; the first survey categorized participants as reluctant, reachable, or endorser. Results: A total of 4,803 participants were included in the analysis. Most (70%) were vaccine endorsers, 16% were reachable, and 14% were reluctant. By May 2021, 77% had received at least one vaccine dose. KAP responses strongly predicted vaccine uptake, particularly positive attitudes about safety (aOR = 5.46, 95% CI: 1.4–20.8) and effectiveness (aOR = 5.0, 95% CI: 1.3–19.1). Participants’ with prior SARS-CoV-2 infection were 22% less likely to believe the COVID-19 vaccine was effective compared with uninfected participants (aOR 0.78, 95% CI: 0.64–0.96). This was even more pronounced in first responders compared with other occupations, with first responders 42% less likely to believe in COVID-19 vaccine effectiveness (aOR = 0.58, 95% CI 0.40–0.84). Between administrations of the two surveys, 25% of reluctant, 56% reachable, and 83% of endorser groups received the COVID-19 vaccine. The reachable group had large increases in positive responses for questions about vaccine safety (10% of vaccinated, 34% of unvaccinated), and vaccine effectiveness (12% of vaccinated, 27% of unvaccinated). Discussion: Our study demonstrates attitudes associated with COVID-19 vaccine uptake and a positive shift in attitudes over time. First responders, despite potential high exposure to SARS-CoV-2, and participants with a history of SARS-CoV-2 infection were more vaccine reluctant. Conclusions: Perceptions of the COVID-19 vaccine can shift over time. Targeting messages about the vaccine's safety and effectiveness in reducing SARS-CoV-2 virus infection and illness severity may increase vaccine uptake for reluctant and reachable participants.
AB - Introduction: In a multi-center prospective cohort of essential workers, we assessed knowledge, attitudes, and practices (KAP) by vaccine intention, prior SARS-CoV-2 positivity, and occupation, and their impact on vaccine uptake over time. Methods: Initiated in July 2020, the HEROES-RECOVER cohort provided socio-demographics and COVID-19 vaccination data. Using two follow-up surveys approximately three months apart, COVID-19 vaccine KAP, intention, and receipt was collected; the first survey categorized participants as reluctant, reachable, or endorser. Results: A total of 4,803 participants were included in the analysis. Most (70%) were vaccine endorsers, 16% were reachable, and 14% were reluctant. By May 2021, 77% had received at least one vaccine dose. KAP responses strongly predicted vaccine uptake, particularly positive attitudes about safety (aOR = 5.46, 95% CI: 1.4–20.8) and effectiveness (aOR = 5.0, 95% CI: 1.3–19.1). Participants’ with prior SARS-CoV-2 infection were 22% less likely to believe the COVID-19 vaccine was effective compared with uninfected participants (aOR 0.78, 95% CI: 0.64–0.96). This was even more pronounced in first responders compared with other occupations, with first responders 42% less likely to believe in COVID-19 vaccine effectiveness (aOR = 0.58, 95% CI 0.40–0.84). Between administrations of the two surveys, 25% of reluctant, 56% reachable, and 83% of endorser groups received the COVID-19 vaccine. The reachable group had large increases in positive responses for questions about vaccine safety (10% of vaccinated, 34% of unvaccinated), and vaccine effectiveness (12% of vaccinated, 27% of unvaccinated). Discussion: Our study demonstrates attitudes associated with COVID-19 vaccine uptake and a positive shift in attitudes over time. First responders, despite potential high exposure to SARS-CoV-2, and participants with a history of SARS-CoV-2 infection were more vaccine reluctant. Conclusions: Perceptions of the COVID-19 vaccine can shift over time. Targeting messages about the vaccine's safety and effectiveness in reducing SARS-CoV-2 virus infection and illness severity may increase vaccine uptake for reluctant and reachable participants.
UR - http://www.scopus.com/inward/record.url?scp=85121126595&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85121126595&partnerID=8YFLogxK
U2 - 10.1016/j.vaccine.2021.11.094
DO - 10.1016/j.vaccine.2021.11.094
M3 - Article
C2 - 34906392
AN - SCOPUS:85121126595
SN - 0264-410X
VL - 40
SP - 494
EP - 502
JO - Vaccine
JF - Vaccine
IS - 3
ER -